Press Releases

Date Title
Toggle Summary Aeglea BioTherapeutics Announces 1-Year Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 6th Congress of the European Academy of Neurology
   Pegzilarginase Showed Durable Clinical Response at 56 Week Analysis All Patients Demonstrated a Marked and Sustained Reduction in Plasma Arginine Favorable Safety Profile, Consistent with Previously Reported Results AUSTIN, Texas , May 26, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc.
Toggle Summary Aeglea BioTherapeutics to Present Late-Breaking 1-Year Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 6th Congress of the European Academy of Neurology
AUSTIN, Texas , May 19, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced it will present a new 56 week
Toggle Summary Aeglea BioTherapeutics Reports First Quarter 2020 Financial Results and Corporate Highlights
Gross Proceeds of $138 Million from April 2020 Public Offering Extends Cash Runway Through 2022 Clinical Trial Application for ACN00177 Approved by MHRA; Progress Toward Phase 1/2 Clinical Trial in Homocystinuria Initiation AUSTIN, Texas , May 07, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics,
Toggle Summary Aeglea BioTherapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
AUSTIN, Texas , April 30, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as solutions for rare and other high-burden diseases, today announced the closing of its public offering of
Toggle Summary Aeglea BioTherapeutics Announces Pricing of $120 Million Public Offering
AUSTIN, Texas , April 28, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases, today announced the pricing of an underwritten
Toggle Summary Aeglea BioTherapeutics Announces Proposed Public Offering
AUSTIN, Texas , April 27, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases, today announced a proposed underwritten public
Toggle Summary Aeglea BioTherapeutics Announces Approval of Clinical Trial Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177)
AUSTIN, Texas , April 08, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as solutions for diseases with high unmet medical need, today announced the approval of its Clinical Trial
Toggle Summary Aeglea BioTherapeutics Reports Fourth-Quarter and Full-Year 2019 Financial Results, Highlights Recent Milestones
Company Expects to Complete Enrollment in Phase 3 Trial for Patients with Arginase 1 Deficiency in Third Quarter of 2020, with Topline Data Expected in First Quarter of 2021 Phase 1/2 Trial for Patients with Homocystinuria to Initiate in Second Quarter of 2020 AUSTIN, Texas , Feb.
Toggle Summary Aeglea BioTherapeutics Submits CTA Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177)
Company Expects to Initiate a Phase 1/2 Trial in the Second Quarter of 2020 AUSTIN, Texas , Jan. 13, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as solutions for diseases with high
Toggle Summary Aeglea BioTherapeutics to Present at 38th Annual J.P. Morgan Healthcare Conference
AUSTIN, Texas , Jan. 06, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as solutions for diseases with high unmet medical need, today announced it will present at the 38 th Annual J.P.
Toggle Summary Aeglea BioTherapeutics to Participate in Upcoming Investor Conferences
AUSTIN, Texas , Nov. 26, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide solutions for diseases with unmet medical need, today announced that Anthony G. Quinn , M.B.
Toggle Summary Aeglea BioTherapeutics Reports Third Quarter 2019 Financial Results and Corporate Highlights
AUSTIN, Texas , Nov. 06, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide solutions for diseases with unmet medical need, today reported financial results for the third quarter ended
Toggle Summary Aeglea BioTherapeutics Strengthens Leadership Team with Appointment of Ravi M. Rao as Chief Medical Officer and Michael C. Hanley as Chief Commercial Officer
AUSTIN, Texas , Nov. 04, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide solutions for diseases with unmet medical need, today announced two additions to its senior management team.
Toggle Summary Aeglea BioTherapeutics to Present at 21st Annual H.C. Wainwright Global Investment Conference
Live Webcast Scheduled for 5:30 p.m. ET on Monday, September 9 AUSTIN, Texas , Sept. 05, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide solutions for diseases with unmet medical
Toggle Summary Aeglea BioTherapeutics Announces Positive 20-Dose Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 2019 SSIEM Symposium
Sustained Control of Plasma Arginine Accompanied by Clinical Response; Overall Clinical Responder Rate of 79% Management to Host Conference Call at 9:00 a.m. ET on Tuesday, September 3 AUSTIN, Texas , Sept. 03, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc.